Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Payables: 2022-2025

Historic Payables for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $1.1 million.

  • bioAffinity Technologies' Payables rose 2.58% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year increase of 70.09%. This contributed to the annual value of $1.2 million for FY2024, which is 91.63% up from last year.
  • As of Q3 2025, bioAffinity Technologies' Payables stood at $1.1 million, which was down 10.44% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Payables ranged from a high of $1.5 million in Q1 2025 and a low of $146,537 during Q1 2023.
  • In the last 3 years, bioAffinity Technologies' Payables had a median value of $852,208 in 2024 and averaged $815,391.
  • Data for bioAffinity Technologies' Payables shows a peak YoY spiked of 388.64% (in 2024) over the last 5 years.
  • Over the past 4 years, bioAffinity Technologies' Payables (Quarterly) stood at $345,042 in 2022, then skyrocketed by 75.28% to $604,789 in 2023, then skyrocketed by 91.63% to $1.2 million in 2024, then grew by 2.58% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.2 million for Q2 2025, and $1.5 million during Q1 2025.